Loading clinical trials...
Loading clinical trials...
A Phase IIIb, Prospective, Multicentre, Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport® Using 2 mL Dilution In Adults With Cervical Dystonia
Conditions
Interventions
Botulinum toxin type A
Locations
41
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Movement Disorders Center of Arizona, LLC
Scottsdale, Arizona, United States
University of Arizona
Tucson, Arizona, United States
East Bay Physician's Group
Berkeley, California, United States
Parkinson's and Movement Disorder Institute
Fountain Valley, California, United States
Loma Linda University Healthcare, Department of Neurology
Loma Linda, California, United States
Start Date
March 1, 2013
Primary Completion Date
October 1, 2015
Completion Date
October 1, 2015
Last Updated
August 7, 2019
NCT06328114
NCT03938363
NCT02689466
NCT02504905
NCT05884528
NCT04849988
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions